The FDA said in draft guidance that drugmakers should avoid using dibutyl phthalate and di(2-ethylhexyl) phthalate as an excipient in pharmaceutical and biologic products because they could be toxic to humans. The agency's Inactive Ingredients Database lists possible alternatives to the two phthalates.
Guidance warns against using 2 phthalates as drug excipient
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|